Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High CholesterolGlobeNewsWire • 09/26/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum TranscriptSeeking Alpha • 09/24/25
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinionGlobeNewsWire • 09/22/25
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP OpinionGlobeNewsWire • 09/22/25
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder studyReuters • 09/19/25
Can Regeneron Change The Paradigm In Multiple Myeloma — And Undercut J&J?Investors Business Daily • 09/19/25
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of OutbreaksGlobeNewsWire • 09/19/25
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone FormationGlobeNewsWire • 09/17/25
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 09/09/25
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung CancerGlobeNewsWire • 09/09/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
Regeneron Announces Updated Presentation Time for Upcoming Investor ConferenceGlobeNewsWire • 09/04/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptSeeking Alpha • 09/04/25
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript)Seeking Alpha • 09/03/25